{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.6","value":"32.1"},{"groupId":"OG001","spread":"28.4","value":"43.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Terminal elimination half-life (t1/2) following a single dose of avapritinib","dispersionType":"Standard Deviation","groups":[{"description":"Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD"}],"paramType":"MEAN","populationDescription":"Patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg QD and available PK samples","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Terminal Elimination Half-life (t1/2)","type":"SECONDARY","unitOfMeasure":"h"}